None listed
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. Age =18 years 2. Patients with persistent atrial fibrillation 3. Patients with atrial fibrillation persisting despite continuous antiarrhythmic drug therapy for =6 weeks 4. Patients who understand the explanation regarding the need for and procedural process of catheter ablation using pulsed field ablation, and who voluntarily provide written informed consent 5. Patients able to undergo follow-up for at least 12 months after the procedure
Exclusion criteria
Exclusion criteria: 1. Patients with a left atrial diameter =6.0 cm, rendering them unsuitable for pulsed field ablation 2. Patients with a history of prior lung surgery or structural cardiac abnormalities that render them unsuitable for pulsed field ablation 3. Patients with contraindications to standard therapy—such as anticoagulation therapy—that must be maintained prior to pulsed field ablation 4. Patients belonging to vulnerable populations in clinical research 5. Patients who have previously undergone catheter ablation or pulsed field ablation for atrial fibrillation 6. Pregnant or breastfeeding women
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of atrial arrhythmia (atrial fibrillation or atrial tachycardia lasting =30 seconds) occurring from 3 months to 1 year after the procedure (assessed by electrocardiogram and 72-hour Holter monitoring) | — |
Secondary
| Measure | Time frame |
|---|---|
| Rate of atrial fibrillation termination during the procedure;Recurrence rate of Atrial fibrillation/Atrial Tachycardia/Atrial flutter individually after the 3-month blanking period;Procedure-related safety (presence of adverse events or complications);Procedure time, fluoroscopy time, and number of energy applications | — |
Countries
Korea, Republic of
Contacts
Keimyung University Dongsan Hospital